N-oxide compounds and uses thereof
By developing sodium channel blocker compounds for mammals, the problem that traditional pain treatments are difficult to adapt to diverse neuropathic pain is solved, and effective analgesic effects on neuropathic pain are achieved.
Patent Information
- Application Number
- CN202380030900.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-28
- Filing Date
- 2023-04-27
- Publication Date
- 2024-11-12
AI Technical Summary
Existing pain treatments are difficult to effectively treat diverse neuropathic pain, especially due to their complex causes and multiple subtypes that traditional therapy cannot be applied in many cases.
A novel sodium channel blocker compound, including N-oxide compounds and pharmaceutical compositions, is provided to treat neuropathic pain by inhibiting the inactivated state of sodium channels. The compounds are used in mammals, especially by oral routes, to prevent and treat pain, including neuropathic pain.
The compound showed significant analgesic effects on neuropathic pain, which can effectively relieve pain, including complex and diverse pain types by blocking the activity of sodium channels.
Smart Images

Figure BDA0005062245210000021 
Figure BDA0005062245210000022 
Figure BDA0005062245210000023
Abstract
Description
Technical Field
[0001] The present disclosure generally relates to N-oxide compounds as sodium channel blockers, pharmaceutical compositions comprising the compounds, methods of treating pain, including neuropathic pain, in mammals by administering the sodium channel blockers to mammals in need of treatment. The present disclosure includes methods of using these sodium channel blockers of the present invention and methods for preparing the sodium channel blockers. Background Art
[0002] Pain is defined by the International Association for the Study of Pain (IASP) as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage". In this second edition, two new terms called neuropathic pain and peripheral neuropathic pain have been introduced. Neuropathic pain is defined by the IASP as "pain initiated or caused by a primary lesion or dysfunction in the peripheral or central nervous system" (IASP, Classification of chronic pain (Second Edition), IASP Press, 2002, page 210).
[0003] The treatment of painful conditions is of significant medical importance and there is currently a global need for new pain therapies. In particular, the urgent need for specific treatments for painful conditions or also treatments of specific painful conditions is reported in many scientific works. Although pain is always subjective, its causes or syndromes can be classified into several subtypes.
[0004] Neuropathic pain, which has developed into a major health problem across a wide range of populations in the last few years, also requires very specific treatment, especially considering that any treatment of neuropathic pain is extremely sensitive to the cause behind the pain. Therefore, due to the highly diverse nature of this universal condition called neuropathic pain, in most cases, a substance that is able to treat one subtype of neuropathic pain cannot, or at least not necessarily, treat other specific subtypes.
[0005] To date, there are more than 100 known types of neuropathic pain. Common acquired causes include viral infections, diabetes, injuries, autoimmune diseases, and nutritional deficiencies. Some neuropathic pain may also be inherited or caused by gene mutations. For purposes of the present invention, subtypes may be included under this heading or considered synonymous.
[0006] Voltage-gated sodium channels (VGSCs) control the flow of sodium ions that trigger the excitability of nociceptors in the peripheral nervous system that sense pain. In humans, nine VGSCs have been identified, and some are associated with genes that alter their function. Sodium channels play an important role in painful neuropathies.
[0007] In particular, gene mutations have been associated with sodium channels Nav1.7, Nav1.8 and Nav1.9. Functional gain mutations in gene SCN9A have been associated with Nav1.7 and a painful neurological disorder called hereditary erythromelalgia (IEM). Gene SCN10A has been associated with Nav1.8 and small fiber neuropathy (a condition that causes severe pain attacks in the hands or feet). It can also cause autonomic pain symptoms, such as palpitations, intestinal problems and abnormal sweating. Nav1.9 has also been associated with mutations that cause painful neuropathy.
[0008] The thiazole compounds disclosed herein provide a new modality for treating neuropathic pain as sodium channel blockers.
[0009] As an example, U.S. Pat. No. 8,822,463 describes that a methylcyclohexane compound represented by the following formula is effective in treating neuropathic pain.
[0010] As another example, U.S. Patent No. 8,541,409 mentions carbamoyloxyarylalkanoylarylpiperazine compounds useful as analgesics as follows.
[0011] Disclosure of the Invention Technical issues It is an object of the present disclosure to provide compounds useful as sodium channel blockers.
[0012] Solution to the problem The present disclosure provides novel compounds of the following formula (I), or optical isomers, stereoisomers or isotopic variants thereof, or pharmaceutically acceptable salts thereof: in R1 is hydrogen, halogen, alkyl, alkoxy or cycloalkyl; R2 is hydrogen, halogen, alkyl, alkoxy, cycloalkyl or a 4-10 membered heterocycloalkyl group including one or more heteroatoms selected from N, O and S; R3 is hydrogen, halogen, alkyl, alkoxy or cycloalkyl; and n is an integer from 0 to 4, wherein the alkyl, alkoxy and cycloalkyl groups are optionally substituted by one or more substituents selected from halogen and hydroxy.
[0013] The compounds of formula (I) can be used to inhibit the inactivated state of sodium channels.
[0014] In some embodiments, the compound of formula (I) is a compound of formula (II): wherein R1, R2, R3 and n are as defined above; and R4 is hydrogen, halogen, alkyl, alkoxy, cycloalkyl or 4-10 membered heterocycloalkyl including one or more heteroatoms selected from N, O and S.
[0015] In another embodiment, a pharmaceutical composition is provided, comprising a therapeutically effective amount of one or more compounds described herein and a pharmaceutically acceptable carrier.
[0016] In yet another embodiment, provided is a method for treating or preventing pain, including neuropathic pain, in a mammal in need thereof by administering a therapeutically effective amount of a compound represented by Formula (I) or Formula (II), or an optical isomer, stereoisomer or isotopic variant thereof, or a pharmaceutically acceptable salt thereof.
[0017] Advantageous Effects of the Invention The compounds of the present disclosure are useful as sodium channel blockers for the treatment of pain, including neuropathic pain.
[0018] Mode for the Invention The following description is merely exemplary in nature and is not intended to limit the present disclosure, application, or uses.
[0019] definition "Alkoxy" is RO-, where R is alkyl. Non-limiting examples of alkoxy include methoxy, ethoxy, and propoxy. In one embodiment, alkoxy is methoxy.
[0020] "Alkyl" refers to a straight or branched saturated hydrocarbon group. In one embodiment, the alkyl group has 1-12 carbon atoms. In some embodiments, the alkyl group is C1-C 10 Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl.
[0021] "Cycloalkyl" refers to a saturated or partially saturated monocyclic, fused polycyclic or spiro polycyclic carbocyclic ring, each carbocyclic ring having 3 to 12 ring atoms.
[0022] "Halo" or "halogen" refers to fluorine (-F), chlorine (-Cl), (-Br) or iodine (-I).
[0023] When a particular group is "substituted" (eg, alkoxy, alkyl, cycloalkyl, etc.), the group may have one or more substituents, for example 1-5 substituents, or 1-3 substituents, or 1-2 substituents independently selected from the list of substituents.
[0024] "Pharmaceutically acceptable" means suitable for use in pharmaceutical preparations, generally recognized as safe for use in animals (and more particularly in humans) for such use, officially approved for such use by a national or state regulatory agency, or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia.
[0025] "Pharmaceutically acceptable carrier" refers to a diluent, adjuvant, excipient or carrier, which alone or together provide a carrier or vehicle with which one or more compounds of the present disclosure are formulated and / or administered, and wherein each ingredient or carrier as a whole is pharmaceutically acceptable.
[0026] "Pharmaceutically acceptable salts" refer to salts that can enhance the desired pharmacological activity. Examples of pharmaceutically acceptable salts include acid addition salts formed with inorganic or organic acids, metal salts, and amine salts. Examples of acid addition salts formed with inorganic acids include salts formed with the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Examples of acid addition salts with organic acids are, for example, salts with acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)-benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethylsulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, 4-methyl-bicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4′-methylenebis(3-hydroxy-2-naphthoic acid), 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid and muconic acid. Examples of metal salts include salts with sodium, potassium, calcium, magnesium, aluminum, iron and zinc ions. Examples of amine salts include salts with ammonia and an organic nitrogen-containing base strong enough to form a salt with a carboxylic acid.
[0027] "Therapeutically effective amount" refers to the amount of a compound that, when administered to a subject for treating a disease, is sufficient to achieve treatment for the disease."Therapeutically effective amount" may vary depending on the compound, the disease and its severity, the age, weight, etc. of the subject to be treated.
[0028] Permissible isomers, such as tautomers, racemates, enantiomers, diastereomers, atropisomers, and isotopic variations are included herein where applicable.
[0029] Compound The present disclosure provides a compound of the following formula (I), or an optical isomer, stereoisomer or isotopic variant thereof, or a pharmaceutically acceptable salt thereof: in R1 is hydrogen, halogen, alkyl, alkoxy or cycloalkyl; R2 is hydrogen, halogen, alkyl, alkoxy, cycloalkyl or a 4-10 membered heterocycloalkyl group including one or more heteroatoms selected from N, O and S; R3 is hydrogen, halogen, alkyl, alkoxy or cycloalkyl; and n is an integer from 0 to 4, wherein the alkyl, alkoxy and cycloalkyl groups are optionally substituted by one or more substituents selected from halogen and hydroxy.
[0030] In one embodiment, R1 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy or C3-C 10 Cycloalkyl; R2 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 Cycloalkyl or 4-10 membered heterocycloalkyl including 1-4 heteroatoms selected from N, O and S; R3 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy or C3-C 10 cycloalkyl; and n is an integer from 0 to 4, wherein the alkyl, alkoxy and cycloalkyl are optionally substituted with 1 to 4 substituents selected from halogen and hydroxy.
[0031] In another embodiment, R1 is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy or C3-C6 cycloalkyl; R2 is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl or 4-10 membered heterocycloalkyl including 1-4 heteroatoms selected from N, O and S; R3 is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy or C3-C6 cycloalkyl; and n is an integer from 0 to 4, wherein alkyl, alkoxy and cycloalkyl are optionally substituted with 1-4 substituents selected from halogen and hydroxy.
[0032] In another embodiment, R1 is hydrogen or halogen.
[0033] In another embodiment, R2 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy or C3-C 10 Cycloalkyl; wherein alkyl, alkoxy and cycloalkyl are optionally substituted by 1 to 4 substituents selected from halogen and hydroxy.
[0034] In another embodiment, R3 is hydrogen or halogen.
[0035] In another embodiment, provided is a compound of the following formula (II), or an optical isomer, stereoisomer or isotopic variant thereof, or a pharmaceutically acceptable salt thereof: in R1 is hydrogen, halogen, alkyl, alkoxy or cycloalkyl; R2 is hydrogen, halogen, alkyl, alkoxy, cycloalkyl or a 4-10 membered heterocycloalkyl group including one or more heteroatoms selected from N, O and S; R3 is hydrogen, halogen, alkyl, alkoxy or cycloalkyl; R4 is hydrogen, halogen, alkyl, alkoxy, cycloalkyl or 4-10 membered heterocycloalkyl including one or more heteroatoms selected from N, O and S; and n is an integer from 0 to 3, wherein the alkyl, alkoxy and cycloalkyl groups are optionally substituted by one or more substituents selected from halogen and hydroxy.
[0036] In another embodiment, R1 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, or C3-C 10 Cycloalkyl; R2 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 Cycloalkyl or 4-10 membered heterocycloalkyl including 1-4 heteroatoms selected from N, O and S; R3 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy or C3-C 10 Cycloalkyl; R4 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 Cycloalkyl or 4-10 membered heterocycloalkyl including 1-4 heteroatoms selected from N, O and S; and n is an integer of 0-3, wherein alkyl, alkoxy and cycloalkyl are optionally substituted by 1-4 substituents selected from halogen and hydroxy.
[0037] In another embodiment, R1 is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy or C3-C6 cycloalkyl; R2 is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl or a 4-10 membered heterocycloalkyl group including 1-4 heteroatoms selected from N, O and S; R3 is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy or C3-C6 cycloalkyl; R4 is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl or a 4-10 membered heterocycloalkyl group including 1-4 heteroatoms selected from N, O and S; and n is an integer from 0 to 3, wherein alkyl, alkoxy and cycloalkyl are optionally substituted with 1-4 substituents selected from halogen and hydroxy.
[0038] In another embodiment, R1 is hydrogen or halogen.
[0039] In another embodiment, R2 is hydrogen, halogen, C1-C6 alkyl or C1-C6 alkoxy; wherein alkyl and alkoxy are optionally substituted with 1-4 substituents selected from halogen and hydroxy.
[0040] In another embodiment, R3 is hydrogen or halogen.
[0041] In another embodiment, R4 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy or C3-C 10 Cycloalkyl; wherein alkyl, alkoxy and cycloalkyl are optionally substituted by 1 to 4 substituents selected from halogen and hydroxy.
[0042] Examples of formula (I) include, but are not limited to, the following compounds: N-[(1-Oxopyridin-1-ium-2-yl)methyl]-3-[4-(trifluoromethyl)phenyl]benzamide; 3-(4-Chlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; N-[(1-pyridin-1-ium-2-oxide)methyl]-3-[4-(trifluoromethoxy)phenyl]benzamide; 3-(3-Chlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; N-[(1-Oxopyridin-1-ium-2-yl)methyl]-3-[3-(trifluoromethyl)phenyl]benzamide; 3-(3,4-Dichlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(3,5-Dichlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; N-[(1-pyridin-1-ium-2-oxide)methyl]-3-[3-(trifluoromethoxy)phenyl]benzamide; 3-(2,4-Dichlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(2,5-Dichlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[2,4-bis(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; N-[(1-Oxidopyridin-1-ium-2-yl)methyl]-3-phenyl-benzamide; 3-(4-tert-Butylphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; N-[(1-oxypyridin-1-ium-2-yl)methyl]-3-(p-tolyl)benzamide; 3-(4-Chloro-2-methyl-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[2-Fluoro-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(3-Chloro-4-fluoro-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4-Fluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(3,4-difluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(2-Chlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; N-[(1-Oxopyridin-1-ium-2-yl)methyl]-3-[2-(trifluoromethyl)phenyl]benzamide; 3-(4-Fluoro-3-methyl-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(m-Tolyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4-isopropylphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(2-Fluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4-Chloro-2-methoxy-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[4-Chloro-2-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4-Chloro-3-methyl-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(3-Chloro-5-fluoro-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4-Chloro-3-fluoro-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(2,4-Difluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(3,5-difluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; N-[(1-Oxopyridin-1-ium-2-yl)methyl]-3-(3,4,5-trifluorophenyl)benzamide; 3-(2,3-Difluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(3-Isopropylphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4-Cyclopropylphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[4-(Difluoromethoxy)phenyl]-N-[(1-pyridinium-1-oxide-2-yl)methyl]benzamide; 3-[2-Methyl-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[4-Fluoro-3-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(2-Methoxyphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[3-Fluoro-5-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[3-Fluoro-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[3-Methyl-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[4-(1-Hydroxy-1-methyl-ethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[3-Methoxy-5-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[2-Methoxy-4-(trifluoromethoxy)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4,5-Difluoro-2-methoxy-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4-Chloro-3-methoxy-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[3-Methoxy-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[4-methoxy-2-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 5-(4-chlorophenyl)-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 5-(3-Chlorophenyl)-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 5-(4-Chloro-2-methoxy-phenyl)-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 5-(3,4-Difluorophenyl)-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 5-[4-Chloro-2-(trifluoromethyl)phenyl]-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 2-Fluoro-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 2-Fluoro-N-[(1-pyridin-1-ium-2-oxide)methyl]-5-[4-(trifluoromethyl)phenyl]benzamide; 2-Fluoro-N-[(1-pyridin-1-ium-2-oxide)methyl]-5-[4-(trifluoromethoxy)phenyl]benzamide; 2-Fluoro-5-[3-methoxy-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 2-Fluoro-5-[3-fluoro-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4-chlorophenyl)-N-[(5-fluoro-1-oxypyridin-1-ium-2-yl)methyl]benzamide; and 2-Chloro-5-(4-chlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0043] Synthesis of compounds In some embodiments, compounds of formula (I) can be prepared by the synthetic methods of Schemes I, II, or III as described below.
[0044] When X and Y are H, the desired compounds can be prepared by the synthetic method described in Scheme 1: Scheme I (1-Oxidopyridin-1-ium-2-yl)methanamine hydrochloride (Int-1) was synthesized by general benzylamine protection, pyridine oxidation and Boc group deprotection as shown in Scheme 1. The desired target compound was obtained by general amide coupling of Int-1 with commercially available corresponding carboxylic acids.
[0045] The details of the reaction conditions described in Scheme I are as follows. A solution of 2-pyridylmethylamine in DCM is treated with Boc2O at 0°C. The concentration of 2-pyridylmethylamine as a starting material is about 0.001-100 molar. The reaction is preferably carried out at ambient temperature. The oxidation of the Boc-protected compound is carried out by an oxidant such as mCPBA or MMPP. About 3 equivalents of the oxidant are used. The reaction is preferably carried out in MeOH at 60°C for 3 hours. As represented in Scheme I, the target compound is synthesized from Int-1 in the following manner: deprotection of the Boc group is carried out using an excess of HCl solution in an organic solvent, followed by amide coupling.
[0046] When R3 is not H, the desired compound can be prepared by the synthetic method described in Scheme II: Solution II As shown in Scheme II, the substituent 2-pyridylmethylamine is coupled with the corresponding carboxylic acid using an amide coupling reagent such as EDC and HOBt. The target compound is synthesized in the oxidation of pyridine.
[0047] The details of the reaction conditions described in Scheme II are the same as those depicted in Scheme I. The concentration of each carboxylic acid as a starting material is between about 0.01 and 0.1 molar.
[0048] When the corresponding carboxylic acid is not commercially available, the desired compound can be prepared by the synthetic method described in Scheme III: Scheme IⅡ As shown in Scheme III, the bromo-carboxylic acid compound and Int-1 are reacted with an amide coupling reagent to provide Int-2. Reaction of a palladium catalyst with an appropriate base and solvent can afford the final target compound.
[0049] The details of the reaction conditions described in Scheme III are as follows. The amide coupling is explained above. A palladium catalyst metal reaction is performed. The general reaction conditions are Pd(dppf)Cl2 as the metal, Na2CO3 as the base, and DME as the solvent. Due to the reactivity of the two raw materials, the metal reaction is carried out by various reaction conditions.
[0050] Pharmaceutical composition In one embodiment, a pharmaceutical composition is provided, which, in addition to one or more compounds described herein, further comprises a pharmaceutically acceptable carrier. In various embodiments, the carrier includes a diluent, an adjuvant, an excipient, a combination of other additives or additives, which alone or together provide a carrier in which the composition can be prepared or applied. The composition can take any suitable form for the desired route of administration. In the case of oral administration of the composition, any suitable oral delivery dosage form can be used, including tablets, capsules (filled with solid or liquid), powders, granules, syrups and other liquids, elixirs, inhalants, lozenges, lozenges and solutions without limitation. Injectable compositions or intravenous infusions are also provided in the form of solutions, suspensions and emulsions.
[0051] In a particular embodiment, the pharmaceutical composition is an oral formulation. Since the compound of formula (I) is fully absorbed orally, it is usually not necessary to resort to parenteral administration. For oral administration, the compound is preferably formulated with a pharmaceutically acceptable carrier. The ratio of carrier to compound will not be critical for the pharmacological effect of the preparation, and the ratio can vary greatly according to the formulation conditions. In tableting, various edible pharmaceutical carriers or mixtures thereof can be included therein. Suitable carriers are, for example, mixtures of lactose, calcium hydrogen phosphate and / or corn starch. Other pharmaceutically acceptable ingredients can be further added, including lubricants, such as magnesium stearate.
[0052] The pharmaceutical composition according to the present disclosure may contain one or more additional therapeutic agents, for example, to increase efficacy or reduce side effects. In one embodiment, the pharmaceutical composition includes one or more active ingredients effective for treating or preventing neuropathic pain, by including anticonvulsants, such as gabapentin, pregabalin, carbamazepine; antidepressants, such as duloxetine, milnacipran; and analgesics, such as opioids, nonsteroidal anti-inflammatory drugs, lidocaine patches, and capsaicin patches.
[0053] Medical practicality Another aspect of the present disclosure is to provide a method for treating or preventing a disease or condition mediated by a sodium channel, comprising administering to the mammal a therapeutically effective amount of one or more compounds of formula (I) or formula (II), or optical isomers, stereoisomers or isotopic variants thereof, or pharmaceutically acceptable salts thereof. In another embodiment, the sodium channel may be one or more selected from the following: NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, and NaV1.9.
[0054] In another embodiment, the disease or condition may be pain. In another embodiment, pain may be selected from pain, acute pain, chronic pain, neuropathic pain, inflammatory pain, visceral pain, nociceptive pain including postoperative pain; and mixed pain types involving viscera, gastrointestinal tract, cranial structures, musculoskeletal system, spine, genitourinary system, cardiovascular system and CNS (central nervous system), including cancer pain, back pain, orofacial pain and chemotherapy-induced pain.
[0055] In view of the mechanism of action described above, the compounds of the present invention can be used to prevent or treat neuropathic pain. Neuropathic pain syndromes include, but are not limited to: small fiber neuropathy, lumbosacral radiculopathy, peripheral neuropathic pain, diabetic neuropathy; sciatica; nonspecific low back pain; multiple sclerosis pain; fibromyalgia; HIV-related neuropathy; neuralgia, such as postherpetic neuralgia and trigeminal neuralgia, Morton's neuralgia, causalgia; and pain caused by physical trauma, amputation, phantom limb, cancer, toxins or chronic inflammatory conditions; central pain, such as pain observed in thalamic syndrome; mixed central and peripheral forms of pain, such as complex regional pain syndrome (CRPS) (also known as reflex sympathetic dystrophy).
[0056] The compounds of the present invention can also be used to treat or prevent chronic pain. Chronic pain includes, but is not limited to, chronic pain caused by inflammation or inflammation-related conditions, osteoarthritis, rheumatoid arthritis, acute injury or trauma, upper or lower back pain (caused by systemic, localized or primary spinal diseases such as radiculopathy), bone pain (attributed to osteoarthritis, osteoporosis, bone metastasis or unknown causes), pelvic pain, pain associated with spinal cord injury, cardiothoracic pain, non-cardiothoracic pain, central post-stroke pain, myofascial pain, sickle cell pain, cancer pain, Fabry disease, AIDS pain, geriatric pain, or pain caused by headache, temporomandibular joint syndrome, gout, fibrosis or thoracic outlet syndrome, especially rheumatoid arthritis and osteoarthritis.
[0057] The compounds of the invention may also be used to treat or prevent acute pain resulting from acute injury, illness, sports medicine injuries, carpal tunnel syndrome, burns / scalds, musculoskeletal sprains and strains, tendon strains, cervicobrachial pain syndrome, dyspepsia, gastric ulcers, duodenal ulcers, dysmenorrhea, endometriosis, or surgery (e.g., open heart surgery or bypass surgery); postoperative pain; kidney stone pain; gallbladder pain; gallstone pain; obstetric pain or dental pain.
[0058] The compounds of the present invention can also be used to treat or prevent headaches, migraines, tension-type headaches, converted migraines or progressive headaches, cluster headaches; and secondary headache disorders, such as those arising from infections, metabolic disorders or other systemic diseases; and other acute headaches caused by exacerbations of the above-mentioned primary headaches and secondary headaches, episodic migraines, and the like.
[0059] In another embodiment, the disease or condition can be selected from neurological disorders, neurodegenerative disorders, inflammatory disorders, gastrointestinal (GI) tract disorders, disorders of the genito-urinary tract, psychiatric disorders, cardiovascular disorders, and neuromuscular disorders. The compounds of the present invention can also be used to treat or prevent neurological disorders, such as epilepsy, including simple partial seizures, complex partial seizures, secondary generalized seizures, further including absence seizures, myoclonic seizures, clonic seizures, tonic seizures, tonic-clonic seizures, and atonic seizures.
[0060] The compounds of the invention may also be used to treat or prevent neurodegenerative disorders of various origins, including Alzheimer's disease, Parkinson's disease and other dementia conditions, such as Lewy bodies, frontotemporal dementia and tauopathies; multiple sclerosis, amyotrophic lateral sclerosis and other parkinsonian syndromes; other spinocerebellar degenerations and Charcot-Marie-Tooth neuropathy, traumatic brain injury, stroke and cerebral ischemia.
[0061] The compounds of the invention inhibit inflammatory processes which affect all body systems. It can therefore be used to treat or prevent inflammatory processes of the musculoskeletal system, the following is a list of examples, but this list does not cover all target conditions: arthritic conditions, such as ankylosing spondylitis, cervical spondylitis, fibromyalgia, gout, juvenile rheumatoid arthritis, lumbosacral arthritis, osteoarthritis, osteoporosis, psoriatic arthritis, rheumatic diseases; conditions affecting the skin and related tissues: eczema, psoriasis, pruritus, dermatitis and inflammatory conditions such as sunburn; respiratory system conditions: asthma, allergic rhinitis and respiratory distress syndrome; lung conditions in which inflammation is involved, such as asthma and bronchitis; chronic obstructive pulmonary disease; disorders of the immune and endocrine systems: periarthritis nodosa, thyroiditis, aplastic anemia, sclerodoma, myasthenia gravis, multiple sclerosis and other demyelinating conditions, encephalomyelitis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis.
[0062] The compounds of the present invention may also be used to treat or prevent gastrointestinal (GI) tract disorders, such as inflammatory bowel disease, including but not limited to ulcerative colitis, Crohn's disease, ileitis, pancreatitis, proctitis, celiac disease, enteropathy, microscopic colitis or collagenous colitis, eosinophilic gastroenteritis or cryptitis following proctocolectomy and ileonatal anastomosis, and irritable bowel syndrome, including any disorder associated with abdominal pain and / or discomfort, such as pyloric spasm, nervous dyspepsia, spastic colon, spastic colitis, spastic bowel, enteric neurosis, functional colitis, mucous colitis, laxative colitis, and functional dyspepsia; and may also be used to treat atrophic gastritis, acne-like gastritis, ulcerative colitis, peptic ulcer, heartburn, and other insults to the GI tract, such as those caused by Helicobacter pylori. pylori), gastroesophageal reflux disease, gastroparesis (e.g. diabetic gastroparesis); and other functional bowel disorders, such as non-ulcer dyspepsia (NUD); vomiting, diarrhea, and inflammation of the internal organs.
[0063] The compounds of the invention can also be used to treat or prevent disorders of the genitourinary tract, such as bladder dysfunction, overactive bladder, prostatitis (chronic bacterial prostatitis and chronic non-bacterial prostatitis), prostadynia, interstitial cystitis, urinary incontinence and benign prostatic hyperplasia, annexities, pelvic inflammation, bartholinitis and vaginitis, especially overactive bladder and urinary incontinence.
[0064] The compounds of the invention may also be used to treat or prevent psychiatric disorders such as bipolar depression, mood disorders, bipolar disorder, anxiety disorders and depression.
[0065] The compounds of the invention may also be used to treat or prevent cardiovascular or neuromuscular disorders, such as tachyarrhythmias, myotonia, arrhythmias, movement disorders, neuroendocrine disorders and ataxias. Example
[0066] Example 1: N-[(1-oxypyridin-1-ium-2-yl)methyl]-3-[4-(trifluoromethyl)phenyl]benzamide To a solution of 3-bromo-N-[(1-pyridin-1-oxide-2-yl)methyl]benzamide (0.95mmol) in DME was added 4-trifluoromethylphenylboronic acid (1.91mmol), Pd(dppf)Cl2 (0.24mmol) and 2N Na2CO3. The reaction mixture was stirred at 100°C for 15min. The reaction mixture was cooled to room temperature and filtered to remove palladium residues. The resulting mixture was extracted with DCM, washed with water and brine. The organic layer was dried over magnesium sulfate and concentrated in vacuo. The crude product was purified by flash column chromatography to provide N-[(1-pyridin-1-oxide-2-yl)methyl]-3-[4-(trifluoromethyl)phenyl]benzamide.
[0067] 1H-NMR (CDCl3, 500MHz) δ = 8.28-8.25 (m, 1H), 8.17 (s, 1H), 7.98-7.96 (m, 1H), 7.82-7.80 (m, 1H), 7.73- 7.71 (m, 4H), 7.58 (dd, J=2.0, 7.5Hz, 1H), 7.54-7.51 (m, 1H), 7.33-7.28 (m, 2H), 4.87 (d, J=6.0Hz, 2H).
[0068] Example 2: 3-(4-chlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 4-chlorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(4-chlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0069] 1H-NMR (CDCl3, 500MHz) δ = 8.25 (d, J = 6.0Hz, 1H), 8.00 (s, 1H), 7.92 (brs, 1H, NH), 7. 75 (d, J=8.0Hz, 1H), 7.66 (d, J=7.5Hz, 1H), 7.56-7.28 (m, 8H), 4.85 (d, J=5.5Hz, 2H).
[0070] Example 3: N-[(1-oxypyridin-1-ium-2-yl)methyl]-3-[4-(trifluoromethoxy)phenyl]benzamide The procedure provided in Example 1 was followed using 4-trifluoromethoxyphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide N-[(1-oxypyridin-1-ium-2-yl)methyl]-3-[4-(trifluoromethoxy)phenyl]benzamide.
[0071] 1H-NMR (CDCl3, 500MHz) δ = 8.26 (d, J = 6.5Hz, 1H), 8.01 (s, 1H), 7.95 (brs, 1H, NH), 7. 77 (d, J=7.5Hz, 1H), 7.67 (d, J=7.5Hz, 1H), 7.61-7.28 (m, 8H), 4.86 (d, J=6.0Hz, 2H).
[0072] Example 4: 3-(3-chlorophenyl)-N-[(1-pyridin-1-oxide-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 3-chlorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(3-chlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0073] 1H-NMR (CDCl3, 500MHz) δ = 8.25-8.23 (m, 1H), 7.92 (s, 1H), 7.83 (brs, 1H, NH ), 7.77-7.75 (m, 1H), 7.67 (d, J=7.5Hz, 2H), 7.58-7.29 (m, 7H), 4.87 (s, 2H).
[0074] Example 5: N-[(1-oxypyridin-1-ium-2-yl)methyl]-3-[3-(trifluoromethyl)phenyl]benzamide The procedure provided in Example 1 was followed using 3-trifluoromethylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide N-[(1-oxypyridin-1-ium-2-yl)methyl]-3-[3-(trifluoromethyl)phenyl]benzamide.
[0075] 1H-NMR (CDCl3, 500MHz) δ = 8.23-8.14 (m, 1H), 8.06 (s, 1H), 7.95 (brs, 1H, NH), 7.78-7.46 (m, 8H), 7.30-7.28 (m, 2H), 4.87 (s, 2H).
[0076] Example 6: 3-(3,4-dichlorophenyl)-N-[(1-pyridin-1-ium-2-oxide)methyl]benzamide The procedure provided in Example 1 was followed using 3,4-dichlorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(3,4-dichlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0077] 1H-NMR (CDCl3, 500MHz) δ=8.25 (d, J=6.5Hz, 1H), 8.03 (s, 1H), 7.95 (brs, 1H, NH), 7.76 (d, J=7.5Hz, 1H), 7.69-7.28 (m, 9H), 4.85 (d, J=6.5Hz, 2H).
[0078] Example 7: 3-(3,5-dichlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 3,5-dichlorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(3,5-dichlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0079] 1H-NMR (CDCl3, 500MHz) δ=8.26 (d, J=6.0Hz, 1H), 8.00 (s, 1H), 7.92 (brs, 1H, NH), 7.78 (d, J=8.0Hz , 1H), 7.65 (t, J=2.5Hz, 1H), 7.57 (dd, J=2.0, 7.5Hz, 1H), 7.48-7.27 (m, 7H), 4.85 (d, J=6.0Hz, 2H).
[0080] Example 8: N-[(1-oxypyridin-1-ium-2-yl)methyl]-3-[3-(trifluoromethoxy)phenyl]benzamide The procedure provided in Example 1 was followed using 3-trifluoromethoxyphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide N-[(1-pyridin-1-yloxy-2-yl)methyl]-3-[3-(trifluoromethoxy)phenyl]benzamide.
[0081] 1H-NMR (CDCl3, 500MHz) δ=8.24 (d, J=6.5Hz, 1H), 7.99 (s, 1H), 7.79 (brs, 1H, NH), 7.78 (d, J=8.0 Hz, 1H), 7.67 (d, J=7.5Hz, 1H), 7.57 (d, J=7.5Hz, 1H), 7.52-7.20 (m, 7H), 4.85 (d, J=6.0Hz, 2H).
[0082] Example 9: 3-(2,4-dichlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 2,4-dichlorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(2,4-dichlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0083] 1H-NMR (CDCl3, 500MHz) δ=8.26 (d, J=6.0Hz, 1H), 7.82 (brs, 1H, NH), 7.79 (dd, J=6.5, 8-0Hz, 2H), 7 .54 (dd, J=1-5, 7.5Hz, 2H), 7.47 (dd, J=2.0, 7.5Hz, 2H), 7.31-7.24 (m, 4H), 4.83 (d, J=6.0Hz, 2H).
[0084] Example 10: 3-(2,5-dichlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 2,5-dichlorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(2,5-dichlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0085] 1H-NMR (CDCl3, 500MHz) δ=8.24 (d, J=6.5Hz, 1H), 7.89 (brs, 1H, NH), 7.82-7.80 (m, 2H), 7.55-7.24 (m, 8H), 4.83 (d, J=6.0Hz, 2H).
[0086] Example 11: 3-[2,4-bis(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 2,4-bis(trifluoromethyl)phenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-[2,4-bis(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0087] 1H-NMR (CDCl3, 500MHz) δ = 8.25 (d, J = 6.0Hz, 1H), 7.99 (s, 1H), 7.86 (brs, 1H, NH), 7.84- 7.82 (m, 2H), 7.50 (s, 1H), 7.48-7.43 (m, 4H), 7.32-7.27 (m, 2H), 4.83 (d, J=6.0Hz, 2H).
[0088] Example 12: N-[(1-oxypyridin-1-ium-2-yl)methyl]-3-phenyl-benzamide The procedure provided in Example 1 was followed using phenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide N-[(1-oxypyridin-1-ium-2-yl)methyl]-3-phenyl-benzamide.
[0089] 1H-NMR (CDCl3, 500MHz) δ=8.24 (d, J=6.0Hz, 1H), 7.03 (s, 1H), 7.95 (brs, 1H, NH), 7.75-7.29 (m, 11H), 4.84 (s, 2H).
[0090] Example 13: 3-(4-tert-Butylphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 4-tert-butylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(4-tert-butylphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0091] 1H-NMR (CDCl3, 500MHz) δ = 8.26 (d, J = 1.0Hz, 1H), 8.04 (s, 1H), 7.88 (brs, 1H, NH), 7.75-7.71 (m, 2 H), 7.57-7.55 (m, 3H), 7.49-7.46 (m, 3H), 7.31-7.27 (m, 2H), 4.87 (d, J=6.5Hz, 2H), 1.37 (s, 9H).
[0092] Example 14: N-[(1-oxypyridin-1-ium-2-yl)methyl]-3-(p-tolyl)benzamide The procedure provided in Example 1 was followed using p-tolylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide N-[(1-oxypyridin-1-oxazolidin-2-yl)methyl]-3-(p-tolyl)benzamide.
[0093] 1H-NMR (CDCl3, 500MHz) δ = 8.24 (d, J = 6.0Hz, 1H), 8.01 (s, 1H), 7.91 (brs, 1H, NH), 7.72 (d, J = 7.5Hz, 1H), 7.68 (d , J=8.0Hz, 1H), 7.55 (d, J=7.5Hz, 1H), 7.49-7.43 (m, 3H), 7.29-7.23 (m, 4H), 4.84 (d, J=6.0Hz, 2H), 2.39 (s, 3H).
[0094] Example 15: 3-(4-Chloro-2-methyl-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 4-chloro-2-methylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(4-chloro-2-methyl-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0095] 1H-NMR (CDCl3, 500MHz) δ=8.24 (d, J=4.5Hz, 1H), 7.90 (brs, 1H, NH), 7.76 (d, J=8.0Hz, 1H), 7.71 (s, 1H), 7.55 (d, J =6.5Hz, 1H), 7.46-7.27 (m, 5H), 7.20 (d, J = 8.5Hz, 1H), 7.11 (d, J = 8.0Hz, 1H), 4.83 (d, J = 5.0Hz, 2H), 2.20 (s, 3H).
[0096] Example 16: 3-[2-Fluoro-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 2-fluoro-4-trifluoromethylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-[2-fluoro-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0097] 1H-NMR (CDCl3, 500MHz) δ=8.24 (d, J=5.5Hz, 1H), 7.98 (s, 2H), 7.83 (d, J=7.5Hz, 1H), 7.67 (d, J=7.5Hz, 1H), 7.58-7.28 (m, 7H), 4.85 (d, J=5.5Hz, 2H).
[0098] Example 17: 3-(3-Chloro-4-fluoro-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 3-chloro-4-fluorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(3-chloro-4-fluoro-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0099] 1H-NMR (CDCl3, 500MHz) δ=8.25 (d, J=6.5Hz, 1H), 7.97 (s, 1H), 7.93 (brs, 1H, NH), 7.76 (d, J=8 .0Hz, 1H), 7.63-7.61 (m, 2H), 7.56 (d, J=7.5Hz, 1H), 7.49-7.28 (m, 5H), 4.85 (d, J=6.0Hz, 2H).
[0100] Example 18: 3-(4-Fluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 4-fluorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(4-fluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0101] 1H-NMR (CDCl3, 500MHz) δ=8.25 (d, J=6.0Hz, 1H), 7.98 (s, 1H), 7.91 (brs, 1H, NH), 7.74 (d, J=7.5Hz, 1H), 7.65 (d, J=7 .0Hz, 1H), 7.56-7.54 (m, 3H), 7.47 (t, J=7.5Hz, 1H), 7.31-7.26 (m, 2H), 7.12 (t, J=8.5Hz, 2H), 4.85 (d, J=4.5Hz, 2H).
[0102] Example 19: 3-(3,4-difluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 3,4-difluorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(3,4-difluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0103] 1H-NMR (CDCl3, 500MHz) δ=8.25 (d, J=6.0Hz, 1H), 7.97 (s, 1H), 7.94 (brs, 1H, NH), 7.76 (d, J=7.5Hz, 1H), 7.63 (d, J= 8.0Hz, 1H), 7.57-7.56 (m, 1H), 7.49-7.46 (m, 1H), 7.41-7.28 (m, 4H), 7.21 (t, J=10.0Hz, 1H), 4.85 (d, J=6.0Hz, 2H).
[0104] Example 20: 3-(2-chlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 2-chlorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(2-chlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0105] 1H-NMR (CDCl3, 500MHz) δ=8.25 (d, J=6.5Hz, 1H), 7.87 (brs, 1H, NH), 7.85 (s, 1H), 7.82 (d, J=7.5Hz, 1H), 7.59-7.28 (m, 9H), 4.85 (d, J=6.0Hz, 2H).
[0106] Example 21: N-[(1-oxypyridin-1-ium-2-yl)methyl]-3-[2-(trifluoromethyl)phenyl]benzamide The procedure provided in Example 1 was followed using 2-trifluoromethylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide N-[(1-oxypyridin-1-ium-2-yl)methyl]-3-[2-(trifluoromethyl)phenyl]benzamide.
[0107] 1H-NMR (CDCl3, 500MHz) δ=8.25 (d, J=6.0Hz, 1H), 7.88 (brs, 1H, NH), 7.84-7.74 (m, 3H), 7.57-7.43 (m, 5H), 7.33-7.28 (m, 3H), 4.84 (d, J=6.5Hz, 2H).
[0108] Example 22: 3-(4-Fluoro-3-methyl-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 4-fluoro-3-methylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(4-fluoro-3-methyl-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0109] 1H-NMR (CDCl3, 500MHz) δ=8.26 (d, J=6.0Hz, 1H), 7.98 (s, 1H), 7.91 (brs, 1H, NH), 7.73 (d, J=7.5Hz, 1H), 7.65 (d, J =7.5Hz, 1H), 7.59 (d, J = 6.5Hz, 1H), 7.47-7.28 (m, 5H), 7.06 (t, J = 9.0Hz, 1H), 4.86 (d, J = 6.0Hz, 2H), 2.33 (s, 3H).
[0110] Example 23: 3-(m-Tolyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 3-methylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(m-tolyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0111] 1H-NMR (CDCl3, 500MHz) δ=8.24 (d, J=6.0Hz, 1H), 8.02 (brs, 1H, NH), 7.90 (s, 1H), 7.74 (d, J=8.0Hz, 1H), 7.69 (d, J=7 .5Hz, 1H), 7.55 (dd, J=2.0, 7.5Hz, 1H), 7.47-7.28 (m, 6H), 7.17 (d, J=7.5Hz, 1H), 4.85 (d, J=6.0Hz, 2H), 2.41 (s, 3H).
[0112] Example 24: 3-(4-isopropylphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 4-isopropylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(4-isopropylphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0113] 1H-NMR (CDCl3, 500MHz) δ=8.27 (d, J=6.5Hz, 1H), 8.03 (s, 1H), 7.91 (brs, 1H, NH), 7.75 (d, J=8.0Hz, 1H), 7.71 (d, J=7.5Hz, 1H) , 7.58-7.54 (m, 3H), 7.47 (t, J=8.0Hz, 1H), 7.34-7.27 (m, 4H), 4.87 (d, J=6.0Hz, 2H), 2.99-2.94 (m, 1H), 1.30 (d, J=7.0Hz, 6H).
[0114] Example 25: 3-(2-Fluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 2-fluorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(2-fluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0115] 1H-NMR (CDCl3, 500MHz) δ=8.08 (s, 1H), 7.82 (s, 1H), 7.74 (d, J=5.0Hz, 1H), 7.51-7.30 (m, 8H), 7.24-7.06 (m, 2H), 4.85 (s, 2H).
[0116] Example 26: 3-(4-Chloro-2-methoxy-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 4-chloro-2-methoxyphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(4-chloro-2-methoxy-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0117] 1H-NMR (CDCl3, 500MHz) δ = 8.26 (d, J = 6.5Hz, 1H), 7.92 (s, 1H), 7.89 (brs, 1H, NH), 7.77 (d, J=8.0Hz, 1H), 7.61 (d, J=7.5Hz, 1H), 7.57 (dd, J=1.5, 7.5Hz, 1H ), 7.45 (t, J=8.0Hz, 1H), 7.33-7.26 (m, 2H), 7.23 (d, J=8.0Hz, 1H), 7.02 (dd, J=2.0, 8.0Hz, 1H), 6.97 (d, J=2.0Hz, 1H), 4.86 (d, J=6.0Hz, 2H), 3.81 (s, 3H).
[0118] Example 27: 3-[4-Chloro-2-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 4-chloro-2-trifluoromethylphenylboronic acid in place of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-[4-chloro-2-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0119] 1H-NMR (CDCl3, 500MHz) δ = 8.24 (dd, J = 1.5, 7.5Hz, 1H), 7.90 (brs, 1H, NH), 7.84-7.81 (m, 1H), 7.73 ( d, J=2.5Hz, 1H), 7.55 (d, J=2.0Hz, 1H), 7.47-7.41 (m, 2H), 7.33-7.24 (m, 5H), 4.83 (d, J=7.5Hz, 2H).
[0120] Example 28: 3-(4-Chloro-3-methyl-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 4-chloro-3-methylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(4-chloro-3-methyl-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0121] 1H-NMR (CDCl3, 500MHz) δ = 8.26 (s, 1H), 8.02 (s, 1H), 7.93 (brs, 1H, NH), 7.76 (d, J = 6.5H z, 1H), 7.68 (d, J=7.5Hz, 1H), 7.61 (s, 1H), 7.49-7.30 (m, 6H), 4.88 (s, 2H), 2.44 (s, 3H).
[0122] Example 29: 3-(3-Chloro-5-fluoro-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 3-chloro-5-fluorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(3-chloro-5-fluoro-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0123] 1H-NMR (CDCl3, 500MHz) δ=8.25 (d, J=6.0Hz, 1H), 7.99 (s, 1H), 7.92 (brs, 1H, NH), 7.78 (d, J=7.5Hz, 1H), 7.64 (d, J=7.5Hz, 1 H), 7.57-7.47 (m, 2H), 7.37 (s, 1H), 7.33-7.27 (m, 2H), 7.19 (d, J=9.5Hz, 1H), 7.08 (d, J=8.5Hz, 1H), 4.85 (d, J=6.0Hz, 2H).
[0124] Example 30: 3-(4-Chloro-3-fluoro-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 4-chloro-3-fluorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(4-chloro-3-fluoro-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0125] 1H-NMR (CDCl3, 500MHz) δ=8.29 (d, J=6.0Hz, 1H), 8.03 (s, 1H), 7.97 (brs, 1H, NH), 7.78 (d, J=8.0Hz, 1H), 7.67 (d, J=1.0Hz, 1H), 7.65 (dd, J=5.0, 6.0Hz, 1H), 7.60 (dd, J=2.0, 8.0Hz, 1H), 7.49-7.28 (m, 5H), 4.87 (d, J=6.0Hz, 2H).
[0126] Example 31: 3-(2,4-difluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 2,4-difluorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(2,4-difluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0127] 1H-NMR (CDCl3, 500MHz) δ=8.25 (d, J=6.0Hz, 1H), 7.92 (s, 1H), 7.90 (brs, 1H, NH), 7.78 (d, J=7.5Hz, 1H), 7.63 (d, J=7.0Hz, 1H), 7. 56 (dd, J=1.0, 6.0Hz, 1H), 7.49 (t, J=7.5Hz, 1H), 7.43-7.40 (m, 1H), 7.38-7.27 (m, 2H), 6.98-6.89 (m, 2H), 4.86 (d, J=6.0Hz, 2H).
[0128] Example 32: 3-(3,5-difluorophenyl)-N.[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 3,5-difluorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(3,5-difluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0129] 1H-NMR (CDCl3, 500MHz) δ=8.27 (d, J=6.0Hz, 1H), 7.99 (s, 1H), 7.94 (brs, 1H, NH), 7.78 (d, J= 7.5Hz, 1H), 7.66-7.27 (m, 5H), 7.13-7.10 (m, 2H), 6.82-6.78 (m, 1H), 4.86 (d, J=6.0Hz, 2H).
[0130] Example 33: N-[(1-oxypyridin-1-ium-2-yl)methyl]-3-(3,4,5-trifluorophenyl)benzamide The procedure provided in Example 1 was followed using 3,4,5-trifluorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide N-[(1-oxypyridin-1-ium-2-yl)methyl]-3-(3,4,5-trifluorophenyl)benzamide.
[0131] 1H-NMR (CDCl3, 500MHz) δ=8.31 (d, J=6.0Hz, 1H), 7.95 (s, 1H), 7.87 (brs, 1H, NH), 7.76 (d, J=8 .0Hz, 1H), 7.64 (d, J=1.5Hz, 1H), 7.62-7.33 (m, 4H), 7.22-7.17 (m, 2H), 4.91 (d, J=6.0Hz, 2H).
[0132] Example 34: 3-(2,3-difluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 2,3-difluorophenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(2,3-difluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0133] 1H-NMR (CDCl3, 500MHz) δ=8.27 (d, J=6.0Hz, 1H), 7.97 (s, 1H), 7.95 (brs, 1H, NH), 7.83 (d, J=8.0Hz, 1H), 7.68 (d, J=7 .5Hz, 1H), 7.58 (d, J=7.5Hz, 1H), 7.52 (t, J=7.5Hz, 1H), 7.35-7.27 (m, 2H), 7.21-7.14 (m, 3H), 4.87 (d, J=6.0Hz, 2H).
[0134] Example 35: 3-(3-isopropylphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 3-isopropylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(3-isopropylphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0135] 1H-NMR (CDCl3, 500MHz) δ=8.25 (d, J=6.5Hz, 1H), 8.03 (s, 1H), 7.89 (brs, 1H, NH), 7.71 (dd, J=7.5, 14.0Hz, 2H ), 7.56 (d, J=7.5Hz, 1H), 7.48-7.29 (m, 7H), 4.85 (d, J=6.0Hz, 2H), 2.99-2.94 (m, 1H), 1.29 (d, J=6.5Hz, 6H).
[0136] Example 36: 3-(4-cyclopropylphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 4-cyclopropylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(4-cyclopropylphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0137] 1H-NMR (CDCl3, 500MHz) δ=8.25 (d, J=6.5Hz, 1H), 8.02 (s, 1H), 7.93 (brs, 1H, NH), 7.74-7.68 (m, 2H), 7.57 (dd, J=2.0, 8.0Hz, 1H), 7.51- 7.45 (m, 3H), 7.33-7.26 (m, 2H), 7.15 (d, J=8.0Hz, 2H), 4.86 (d, J=6.0Hz, 2H), 1.97-1.92 (m, 1H), 1.03-0.98 (m, 2H), 0.77-0.75 (m, 2H).
[0138] Example 37: 3-[4-(Difluoromethoxy)phenyl]-N-[(1-pyridin-1-ium-2-oxide)methyl]benzamide The procedure provided in Example 1 was followed using 4-difluoromethoxyphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-[4-(difluoromethoxy)phenyl]-N-[(1-pyridin-1-ium-2-oxygenyl)methyl]benzamide.
[0139] 1H-NMR (CDCl3, 500MHz) δ = 8.26 (d, J = 6.5Hz, 1H), 8.02 (s, 1H), 7.97 (brs, 1H, NH), 7.78-7.51 (m , 5H), 7.34-7.29 (m, 3H), 7.22 (d, J=8.5Hz, 2H), 6.58 (d, J=74.0Hz, 1H), 4.88 (d, J=6.0Hz, 2H).
[0140] Example 38: 3-[2-methyl-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 2-methyl-4-(trifluoromethyl)phenylboronic acid in place of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-[2-methyl-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0141] 1H-NMR (CDCl3, 500MHz) δ = 8.25 (d, J = 6.5Hz, 1H), 7.97 (brs, 1H, NH), 7.83 (d, J = 7.5Hz, 1H), 7.75 (s, 1H), 7.53-7.27 (m, 8H), 4.85 (d, J=6.5Hz, 2H), 2.29 (s, 3H).
[0142] Example 39: 3-[4-Fluoro-3-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 4-fluoro-3-trifluoromethylphenylboronic acid in place of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-[4-fluoro-3-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0143] 1H-NMR (CDCl3, 500MHz) δ=8.25 (d, J=6.5Hz, 1H), 8.03 (s, 1H), 7.89 (brs, 1H, NH), 7.84-7.33 (m, 9H), 4.90 (d, J=6.5Hz, 2H).
[0144] Example 40: 3-(2-methoxyphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 2-methoxyphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(2-methoxyphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0145] 1H-NMR (CDCl3, 500MHz) δ=8.31 (d, J=6.0Hz, 1H), 7.95 (s, 1H), 7.87 (brs, 1H, NH), 7.79 (d, J=7.5Hz, 1H), 7.70 (d, J=8.0Hz, 1H), 7.59 (d, J =7.0Hz, 1H), 7.49 (t, J = 7.5Hz, 1H), 7.40-7.30 (m, 4H), 7.07 (t, J = 7.0Hz, 1H), 7.03 (d, J = 8.0Hz, 1H), 4.89 (d, J = 5.0Hz, 2H), 3.85 (s, 3H).
[0146] Example 41: 3-[3-Fluoro-5-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 3-fluoro-5-trifluoromethylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-[3-fluoro-5-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0147] 1H-NMR (CDCl3, 500MHz) δ=8.36 (d, J=6.0Hz, 1H), 8.11 (s, 1H), 8.04 (brs, 1H, NH), 7.83 (d, J=7.5Hz, 1 H), 7.74 (d, J=8.0Hz, 1H), 7.68 (s, 1H), 7.61-7.52 (m, 4H), 7.38-7.30 (m, 2H), 4.89 (d, J=6.0Hz, 2H).
[0148] Example 42: 3-[3-Fluoro-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 3-fluoro-4-trifluoromethylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-[3-fluoro-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0149] 1H-NMR (CDCl3, 500MHz) δ=8.31 (d, J=6.0Hz, 1H), 8.19 (s, 1H), 7.99 (brs, 1H, NH), 7.83 (d, J=7.5Hz, 1H), 7.72-7.30 (m, 8H), 4.88 (d, J=6.0Hz, 2H).
[0150] Example 43: 3-[3-methyl-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 3-methyl-4-trifluoromethylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-[3-methyl-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0151] 1H-NMR (CDCl3, 500MHz) δ = 8.39 (d, J = 6.0Hz, 1H), 8.08 (s, 1H), 7.94 (brs, 1H, NH ), 7.80 (d, J=7.5Hz, 1H), 7.73-7.29 (m, 8H), 4.88 (d, J=6.0Hz, 2H), 2.57 (s, 3H).
[0152] Example 44: 3-[4-(1-Hydroxy-1-methyl-ethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 1-hydroxy-1-methyl-ethylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-[4-(1-hydroxy-1-methyl-ethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0153] 1H-NMR (CDCl3, 500MHz) δ = 8.26 (d, J = 6.0Hz, 1H), 8.05 (s, 1H), 7.92 (brs, 1H, NH), 7.76 (d, J =7.5Hz, 1H), 7.73 (d, J = 8.0Hz, 1H), 7.61-7.28 (m, 8H), 4.88 (d, J = 6.0Hz, 2H), 1.64 (s, 6H).
[0154] Example 45: 3-[3-methoxy-5-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 3-methoxy-5-trifluoromethylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-[3-methoxy-5-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0155] 1H-NMR (CDCl3, 500MHz) δ=8.27 (d, J=6.0Hz, 1H), 8.06 (s, 1H), 7.92 (brs, 1H, NH), 7.79 (d, J=7.5H z, 1H), 7.72 (d, J=8.0Hz, 1H), 7.59-7.30 (m, 6H), 7.14 (s, 1H), 4.88 (d, J=6.0Hz, 2H), 3.92 (s, 3H).
[0156] Example 46: 3-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 2-methoxy-4-trifluoromethoxyphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0157] 1H-NMR (CDCl3, 500MHz) δ=8.24 (d, J=6.0Hz, 1H), 7.91 (s, 1H), 7.86 (brs, 1H, NH), 7.77 (d, J=7.5Hz, 1H), 7.61 (d, J=8.0Hz, 1H ), 7.55-7.28 (m, 5H), 6.90 (d, J=7.0Hz, 1H), 6.82 (s, 1H), 7.59-7.30 (m, 6H), 7.14 (s, 1H), 4.85 (d, J=6.0Hz, 2H), 3-82 (s, 3H).
[0158] Example 47: 3-(4,5-Difluoro-2-methoxy-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 4,5-difluoro-2-methoxyphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(4,5-difluoro-2-methoxy-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0159] 1H-NMR (CDCl3, 500MHz) δ=8.25 (d, J=6.0Hz, 1H), 7.89 (s, 1H), 7.88 (brs, 1H, NH), 7.76 (d, J=2.5Hz, 1H), 7.58-7.54 (m, 2H), 7.4 5 (t, J=7.5Hz, 1H), 7.30-7.28 (m, 2H), 7.13 (t, J=10.0Hz, 1H), 6.79 (dd, J=7.0, 12.0Hz, 1H), 4.84 (d, J=6.0Hz, 2H), 3.76 (s, 3H).
[0160] Example 48: 3-(4-Chloro-3-methoxy-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 4-chloro-3-methoxyphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-(4-chloro-3-methoxy-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0161] 1H-NMR (CDCl3, 500MHz) δ = 8.25 (d, J = 6.0Hz, 1H), 8.01 (s, 1H), 7.91 (brs, 1H, NH), 7.75-7.73 (m, 1H), 7.68-7.66 (m, 1 H), 7.56-7.50 (m, 1H), 7.48-7.41 (m, 2H), 7.31-7.27 (m, 2H), 7.12-7.10 (m, 2H), 4.85 (d, J=6.0Hz, 2H), 3.79 (s, 3H).
[0162] Example 49: 3-[3-methoxy-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 3-methoxy-4-trifluoromethylphenylboronic acid instead of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-[3-methoxy-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0163] 1H-NMR (CDCl3, 500MHz) δ = 8.24 (d, J = 6.0Hz, 1H), 8.03 (s, 1H), 7.96 (brs, 1H, N H), 7.72-7.27 (m, 7H), 7.22-7.18 (m, 2H), 4.90 (d, J=6.0Hz, 2H), 3.98 (s, 3H).
[0164] Example 50: 3-[4-methoxy-2-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 1 was followed using 4-methoxy-2-trifluoromethylphenylboronic acid in place of 4-trifluoromethylphenylboronic acid as the reactant to provide 3-[4-methoxy-2-(trifluoromethyl)phenyl]-N-[(1-pyridin-1-ium-2-oxygenyl)methyl]benzamide.
[0165] 1H-NMR (CDCl3, 500MHz) δ=8.25 (d, J=6.0Hz, 1H), 7.91-7.80 (m, 2H), 7.73 (s, 1H), 7.54 (dd, J=2.0, 7.5Hz, 1H ), 7.43 (d, J=5.5Hz, 2H), 7.31-7.21 (m, 4H), 7.07 (dd, J=2.5, 8.5Hz, 1H), 4.83 (d, J=6.0Hz, 2H), 3.89 (s, 3H).
[0166] Example 51: 5-(4-chlorophenyl)-2-fluoro-N-[(1-pyridin-1-ium-2-oxide)methyl]benzamide The procedure provided in Example 1 was followed using 4-chlorophenylboronic acid and 5-bromo-2-fluoro-N-[(1-pyridin-1-ium-2-oxide)methyl]benzamide instead of 4-trifluoromethylphenylboronic acid and 3-bromo-N-[(1-pyridin-1-ium-2-oxide)methyl]benzamide as reactants, respectively, to provide 5-(4-chlorophenyl)-2-fluoro-N-[(1-pyridin-1-ium-2-oxide)methyl]benzamide.
[0167] 1H-NMR (CDCl3, 500MHz) δ=8.25-8.19 (m, 2H), 8.18 (brs, 1H, NH), 7.63 (dq, J=2.5, 4.5Hz, 1H), 7.55 (d, J=2.0Hz, 1H), 7.53 (d, J=2.0Hz, 2H), 7.49 (d, J=8.5Hz, 2H), 7.41-7.29 (m, 2H), 7.21-7.17 (m, 1H), 4.88 (d, J=6.0Hz, 2H).
[0168] Example 52: 5-(3-chlorophenyl)-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 51 was followed using 3-chlorophenylboronic acid instead of 4-chlorophenylboronic acid as the reactant to provide 5-(3-chlorophenyl)-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0169] 1H-NMR (CDCl3, 500MHz) δ = 8.28-8.24 (m, 3H), 7.65-7.18 (m, 9H), 4.88 (d, J = 6.0Hz, 2H).
[0170] Example 53: 5-(4-Chloro-2-methoxy-phenyl)-2-fluoro-N-[(1.2-pyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 51 was followed using 4-chloro-2-methoxyphenylboronic acid in place of 4-chlorophenylboronic acid as the reactant to provide 5-(4-chloro-2-methoxy-phenyl)-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0171] 1H-NMR (CDCl3, 500MHz) δ=8.27 (d, J=6.0Hz, 1H), 8.14-8.12 (m, 2H), 7.53-7.51 (m, 2H), 7.28-7.26 (m, 2H), 7.20 (d, J=8. 0Hz, 1H), 7.15 (t, J=3.0Hz, 1H), 6.99 (dd, J=1.5, 5.0Hz, 1H), 6.94 (d, J=2.0Hz, 1H), 4.87 (d, J=6.0Hz, 2H), 3.79 (s, 3H).
[0172] Example 54: 5-(3,4-difluorophenyl)-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 51 was followed using 3,4-difluorophenylboronic acid instead of 4-chlorophenylboronic acid as the reactant to provide 5-(3,4-difluorophenyl)-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0173] 1H-NMR (CDCl3, 500MHz) δ = 8.30-8.19 (m, 3H), 7.61-7.18 (m, 7H), 4.87 (d, J = 6.0Hz, 2H).
[0174] Example 55: 5-[4-Chloro-2-(trifluoromethyl)phenyl]-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 51 was followed using 4-chloro-2-trifluoromethylphenylboronic acid in place of 4-chlorophenylboronic acid as the reactant to provide 5-[4-chloro-2-(trifluoromethyl)phenyl]-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0175] 1H-NMR (CDCl3, 500MHz) δ=8.29 (d, J=6.0Hz, 1H), 8.27 (brs, 1H, NH), 7.99 (dd, J=2.5, 7.0Hz, 1H) , 7.73 (d, J=2.0Hz, 1H), 7.54-7.23 (m, 7H), 7.17 (dd, J=8.5, 11.5Hz, 1H), 4.86 (d, J=6.0Hz, 2H).
[0176] Example 56: 2-Fluoro-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 51 was followed using 2-methoxy-4-trifluoromethoxyphenylboronic acid in place of 4-chlorophenylboronic acid as the reactant to provide 2-fluoro-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0177] 1H-NMR (CDCl3, 500MHz) δ=8.26 (d, J=1.5Hz, 1H), 8.13 (dd, J=2.5, 7.5Hz, 2H), 7.58 (dt, J=2.5, 5.0Hz, 1H), 7.51 (dd, J=2.5, 7.5Hz, 1H), 7.29-7.25 (m, 3H), 7.15 (dd, J=9.0, 12.0Hz, 1H), 6.87 (dd, J=1.0, 8.5Hz, 1H), 6.80 (d, J=2.0Hz, 1H), 4.86 (d, J=6.0Hz, 2H), 3.80 (s, 3H).
[0178] Example 57: 2-Fluoro-N-[(1-pyridin-1-ium-2-oxide)methyl]-5-[4-(trifluoromethyl)phenyl]benzamide The procedure provided in Example 51 was followed using 4-trifluoromethylphenylboronic acid instead of 4-chlorophenylboronic acid as the reactant to provide 2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]-5-[4-(trifluoromethyl)phenyl]benzamide.
[0179] 1H-NMR (CDCl3, 500MHz) δ=8.24-8.22 (m, 3H), 7.64-7.61 (m, 5H), 7.49 (dd, J=2.0, 7.5Hz, 1H), 7.24-7.15 (m, 3H), 4.84 (d, J=6.0Hz, 2H).
[0180] Example 58: 2-Fluoro.N-[(1-pyridin-1-ium-2-oxide)methyl]-5-[4-(trifluoromethoxy)phenyl]benzamide The procedure provided in Example 51 was followed using 4-trifluoromethoxyphenylboronic acid instead of 4-chlorophenylboronic acid as the reactant to provide 2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]-5-[4-(trifluoromethoxy)phenyl]benzamide.
[0181] 1H-NMR (CDCl3, 500MHz) δ = 8.28-8.18 (m, 3H), 7.64-7.53 (m, 4H), 7.32-7.18 (m, 5H), 4.89 (d, J = 5.0Hz, 2H).
[0182] Example 59: 2-Fluoro-5-[3-methoxy-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 51 was followed using 3-methoxy[4-trifluoromethylphenylboronic acid in place of 4-chlorophenylboronic acid as the reactant to provide 2-fluoro-5-[3-methoxy-4-(trifluoromethyl)phenyl]-N-[(1-pyridin-1-ium-2-oxygenyl)methyl]benzamide.
[0183] 1H-NMR (CDCl3, 500MHz) δ = 8.29-8.21 (m, 3H), 7.68-7.53 (m, 3H), 7.32-7.16 (m, 4H), 7.14 (s, 1H), 4.89 (d, J = 6.0Hz, 2H), 3.96 (s, 3H).
[0184] Example 60: 2-Fluoro-5-[3-fluoro-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 51 was followed using 3-fluoro-4-trifluoromethylphenylboronic acid instead of 4-chlorophenylboronic acid as the reactant to provide 2-fluoro-5-[3-fluoro-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
[0185] 1H-NMR (CDCl3, 500MHz) δ = 8.29-8.23 (m, 3H), 7.67-7.38 (m, 5H), 7.31-7.21 (m, 3H), 4.86 (d, J = 5.5Hz, 2H).
[0186] Example 61: 3-(4-chlorophenyl)-N-[(5-fluoro-1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 51 was followed using 3-(4-chlorophenyl)-N-[(5-fluoro-2-pyridinyl)methyl]benzamide, 3-bromo-5-fluoro-N-[(1-pyridin-1-ium-2-oxide)methyl]benzamide instead of 5-bromo-2-fluoro-N-[(1-pyridin-1-ium-2-oxide)methyl]benzamide as the reactant to provide 3-(4-chlorophenyl)-N-[(5-fluoro-1-pyridin-1-ium-2-oxide)methyl]benzamide.
[0187] 1H-NMR (CDCl3, 500MHz) δ=8.19 (dd, J=2.5, 4.0Hz, 1H), 7.99 (d, J=1.5Hz, 1H), 7.75 (d, J=1 .0Hz, 1H), 7.73 (brs, 1H, NH), 7.69-7.41 (m, 7H), 7.13-7.09 (m, 1H), 4.81 (d, J=6.0Hz, 2H).
[0188] Example 62: 2-Chloro-5-(4-chlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide The procedure provided in Example 51 was followed using 5-bromo-2-chloro-N-[(1-pyridin-1-ium-2-oxide)methyl]benzamide instead of 5-bromo-2-fluoro-N-[(1-pyridin-1-ium-2-oxide)methyl]benzamide as the reactant to provide 2-chloro-5-(4-chlorophenyl)-N-[(1-pyridin-1-ium-2-oxide)methyl]benzamide.
[0189] 1H-NMR (DMSO-d6, 500MHz) δ=9.17 (t, J=7.5Hz, 1H), 8.34-8.32 (m, 2H), 7.88 (d, J=3.0Hz, 1H), 7.81-7.37 (m, 7H), 4.56 (d, J=7.5Hz, 2H).
[0190] hNav1.7 channel assay The whole-cell patch clamp technique was used to investigate the inhibitory effects of the compounds of the examples on human Nav1.7 channels stably expressed in HEK293 cells. Human Nav1.7 recombinant cell line (CYL3011-precisION) was purchased from Eurofins.
[0191] The state-dependent inhibition of the embodiment was evaluated using a two-pulse protocol every 10 seconds. From a holding potential of -90 mV, a pre-pulse (200 ms at -120 mV) was followed by a test pulse 1 (TP1: 1 s at 0 mV), and then a test pulse 2 (TP2: 20 ms at 0 mV) was triggered after a spacer pulse (20 ms at -100 mV).
[0192] Peak current amplitudes of test pulses TP1 (resting period inhibition) and TP2 (inactivation period inhibition) were measured. The following solutions were used for the screening assay: External (mM): 145 NaCl, 1 MgCl2, 1.8 CaCl2, 10 Hepes, 5 glucose, pH 7.4, 300 mOsm; Internal (mM): 120 CsF, 10 NaCl, 10 EGTA, 10 HEPES, pH 7.2, 290 mOsm.
[0193] The inhibition of the inactive state of hNav1.7 was calculated as: % inhibition (inactive state) = (1-(I TP2 ,TA / I TP2 , control) x 100%, where I TP2 (inward peak Na+ current), control and l TP2 , TA was elicited by TP2 in control (vehicle only) and in the presence of the test articles of the indicated examples (TA), respectively.
[0194] According to one embodiment of the present invention, the compounds of Examples did not show significant inhibition of the resting state of hNav1.7, which indicates a relatively low adverse possibility of Examples. [Table 1]
[0195] The inhibitory activity represents the % inhibition of the inactivated state of hNav1.7 at 10 μM. +: 10-40%, ++: 40-70%, +++: 70-100%
[0196] As described herein, it was observed that the compounds of the present disclosure have inhibitory affinity for voltage-dependent sodium channels. The results indicate that the compounds can be used to treat pain, including neuropathic pain, by blocking the activity of sodium channels.
[0197] Rat spinal nerve ligation model Analgesic efficacy was examined by the spinal nerve ligation (SNL) model, also known as the Chung model (Kim and Chung, 1992). The SNL model is one of the most frequently used animal models for evaluating neuropathic pain behaviors.
[0198] In brief, the lumbar 5 spinal nerve was ligated with silk sutures distal to the dorsal root ganglion. After two weeks of recovery, the mechanical allodynia of the affected paws of the animals was assessed using von Frey filaments. Using the Dixons Up-Down method (Chaplan et al., 1994), a pre-dose baseline was obtained when allodynia was defined as a paw withdrawal threshold (PWT) <4g. The test compound (30 mg / kg) or vehicle was then orally administered, and PWT was measured two hours after treatment. The PWT statistical mean of the vehicle control group and the drug-treated group was calculated, and the maximum possible effect percentage (%MPE) value was determined according to the following formula; %MPE = [(PWT after administration-PWT before administration) / (cutoff PWT-PWT before administration)] × 100. [Table 2] Example In vivo effects Example 2 +++ Example 3 ++ Embodiment 14 ++ Embodiment 19 ++ Embodiment 22 + Embodiment 51 +++ In vivo efficacy is expressed as % MPE at oral administration of 30 mg / kg. +: 10-40%, ++: 40-70%, +++: 70-100%
[0199] As described above, the compounds of the present disclosure are observed to have analgesic efficacy, which are useful in treating pain, including neuropathic pain.
Claims
1. A compound of the following formula (I), or an optical isomer, stereoisomer or isotopic variant thereof, or a pharmaceutically acceptable salt thereof: in R1 is hydrogen, halogen, alkyl, alkoxy or cycloalkyl; R2 is hydrogen, halogen, alkyl, alkoxy, cycloalkyl or a 4-10 membered heterocycloalkyl group including one or more heteroatoms selected from N, O and S; R3 is hydrogen, halogen, alkyl, alkoxy or cycloalkyl; and n is an integer from 0 to 4, The alkyl, alkoxy and cycloalkyl groups are optionally substituted by one or more substituents selected from halogen and hydroxy.
2. The compound according to claim 1, or its optical isomer, stereoisomer or isotopic variant, or its pharmaceutically acceptable salt, wherein R1 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy or C3-C 10 Cycloalkyl; R2 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 Cycloalkyl or 4-10 membered heterocycloalkyl including 1-4 heteroatoms selected from N, O and S; R3 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy or C3-C 10 cycloalkyl; and n is an integer from 0 to 4, The alkyl, alkoxy and cycloalkyl groups are optionally substituted by 1 to 4 substituents selected from halogen and hydroxy.
3. The compound according to claim 1, or its optical isomer, stereoisomer or isotopic variant, or its pharmaceutically acceptable salt, wherein R1 is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy or C3-C6 cycloalkyl; R2 is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl or 4-10 membered heterocycloalkyl including 1-4 heteroatoms selected from N, O and S; R3 is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy or C3-C6 cycloalkyl; and n is an integer from 0 to 4, The alkyl, alkoxy and cycloalkyl groups are optionally substituted by 1 to 4 substituents selected from halogen and hydroxy.
4. The compound according to claim 1, or its optical isomer, stereoisomer or isotopic variant, or its pharmaceutically acceptable salt, wherein R1 is hydrogen or halogen.
5. The compound according to claim 1, or its optical isomer, stereoisomer or isotopic variant, or its pharmaceutically acceptable salt, wherein R2 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy or C3-C 10 Cycloalkyl; The alkyl, alkoxy and cycloalkyl groups are optionally substituted by 1 to 4 substituents selected from halogen and hydroxy.
6. The compound according to claim 1, or its optical isomer, stereoisomer or isotopic variant, or its pharmaceutically acceptable salt, wherein R3 is hydrogen or halogen.
7. The compound according to claim 1, or its optical isomer, stereoisomer or isotopic variant, or its pharmaceutically acceptable salt, wherein the compound of formula (I) is a compound of formula (II): in R1 is hydrogen, halogen, alkyl, alkoxy or cycloalkyl; R2 is hydrogen, halogen, alkyl, alkoxy, cycloalkyl or a 4-10 membered heterocycloalkyl group including one or more heteroatoms selected from N, O and S; R3 is hydrogen, halogen, alkyl, alkoxy or cycloalkyl; R4 is hydrogen, halogen, alkyl, alkoxy, cycloalkyl or 4-10 membered heterocycloalkyl including one or more heteroatoms selected from N, O and S; and n is an integer from 0 to 3, The alkyl, alkoxy and cycloalkyl groups are optionally substituted by one or more substituents selected from halogen and hydroxy.
8. The compound according to claim 7, or its optical isomer, stereoisomer or isotopic variant, or its pharmaceutically acceptable salt, wherein R1 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy or C3-C 10 Cycloalkyl; R2 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 Cycloalkyl or 4-10 membered heterocycloalkyl including 1-4 heteroatoms selected from N, O and S; R3 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy or C3-C 10 Cycloalkyl; R4 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C3-C 10 Cycloalkyl or 4-10 membered heterocycloalkyl including 1-4 heteroatoms selected from N, O and S; and n is an integer from 0 to 3, The alkyl, alkoxy and cycloalkyl groups are optionally substituted by 1 to 4 substituents selected from halogen and hydroxy.
9. The compound according to claim 7, or its optical isomer, stereoisomer or isotopic variant, or its pharmaceutically acceptable salt, wherein R1 is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy or C3-C6 cycloalkyl; R2 is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl or 4-10 membered heterocycloalkyl including 1-4 heteroatoms selected from N, O and S; R3 is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy or C3-C6 cycloalkyl; R4 is hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl or 4-10 membered heterocycloalkyl including 1-4 heteroatoms selected from N, O and S; and n is an integer from 0 to 3, The alkyl, alkoxy and cycloalkyl groups are optionally substituted by 1 to 4 substituents selected from halogen and hydroxy.
10. The compound according to claim 7, or its optical isomer, stereoisomer or isotopic variant, or its pharmaceutically acceptable salt, wherein R1 is hydrogen or halogen.
11. The compound according to claim 7, or its optical isomer, stereoisomer or isotopic variant, or its pharmaceutically acceptable salt, wherein R2 is hydrogen, halogen, C1-C6 alkyl or C1-C6 alkoxy; The alkyl and alkoxy groups are optionally substituted by 1 to 4 substituents selected from halogen and hydroxy.
12. The compound according to claim 7, or its optical isomer, stereoisomer or isotopic variant, or its pharmaceutically acceptable salt, wherein R3 is hydrogen or halogen.
13. The compound according to claim 7, or its optical isomer, stereoisomer or isotopic variant, or its pharmaceutically acceptable salt, wherein R4 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy or C3-C 10 Cycloalkyl; The alkyl, alkoxy and cycloalkyl groups are optionally substituted by 1 to 4 substituents selected from halogen and hydroxy.
14. The compound according to claim 1, or its optical isomer, stereoisomer or isotopic variant, or a pharmaceutically acceptable salt thereof, selected from: N-[(1-pyridin-1-ium-2-oxide)methyl]-3-[4-(trifluoromethyl)phenyl]benzamide; 3-(4-Chlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; N-[(1-pyridin-1-ium-2-oxide)methyl]-3-[4-(trifluoromethoxy)phenyl]benzamide; 3-(3-chlorophenyl)-N-[(1-pyridin-1-ium-2-oxide)methyl]benzamide; N-[(1-Oxopyridin-1-ium-2-yl)methyl]-3-[3-(trifluoromethyl)phenyl]benzamide; 3-(3,4-Dichlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(3,5-Dichlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; N-[(1-pyridin-1-ium-2-oxide)methyl]-3-[3-(trifluoromethoxy)phenyl]benzamide; 3-(2,4-dichlorophenyl)-N-[(1-pyridin-1-ium-2-oxide)methyl]benzamide; 3-(2,5-Dichlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[2,4-bis(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; N-[(1-Oxidopyridin-1-ium-2-yl)methyl]-3-phenyl-benzamide; 3-(4-tert-Butylphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; N-[(1-oxypyridin-1-ium-2-yl)methyl]-3-(p-tolyl)benzamide; 3-(4-Chloro-2-methyl-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[2-Fluoro-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(3-Chloro-4-fluoro-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4-Fluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(3,4-Difluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(2-Chlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; N-[(1-Oxopyridin-1-ium-2-yl)methyl]-3-[2-(trifluoromethyl)phenyl]benzamide; 3-(4-Fluoro-3-methyl-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(m-Tolyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4-isopropylphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(2-Fluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4-Chloro-2-methoxy-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[4-Chloro-2-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4-Chloro-3-methyl-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(3-Chloro-5-fluoro-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4-Chloro-3-fluoro-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(2,4-Difluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(3,5-difluorophenyl)-N-[(1-pyridin-1-ium-2-oxide)methyl]benzamide; N-[(1-pyridin-1-ium-2-oxide)methyl]-3-(3,4,5-trifluorophenyl)benzamide; 3-(2,3-Difluorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(3-Isopropylphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4-Cyclopropylphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[4-(Difluoromethoxy)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[2-Methyl-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[4-Fluoro-3-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(2-Methoxyphenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[3-Fluoro-5-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[3-Fluoro-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[3-Methyl-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[4-(1-Hydroxy-1-methyl-ethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[3-Methoxy-5-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[2-Methoxy-4-(trifluoromethoxy)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4,5-Difluoro-2-methoxy-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4-Chloro-3-methoxy-phenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[3-Methoxy-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-[4-methoxy-2-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 5-(4-Chlorophenyl)-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 5-(3-Chlorophenyl)-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 5-(4-Chloro-2-methoxy-phenyl)-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 5-(3,4-Difluorophenyl)-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 5-[4-Chloro-2-(trifluoromethyl)phenyl]-2-fluoro-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 2-Fluoro-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 2-Fluoro-N-[(1-pyridin-1-ium-2-oxide)methyl]-5-[4-(trifluoromethyl)phenyl]benzamide; 2-Fluoro-N-[(1-pyridin-1-ium-2-oxide)methyl]-5-[4-(trifluoromethoxy)phenyl]benzamide; 2-Fluoro-5-[3-methoxy-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 2-Fluoro-5-[3-fluoro-4-(trifluoromethyl)phenyl]-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide; 3-(4-chlorophenyl)-N-[(5-fluoro-1-oxypyridin-1-ium-2-yl)methyl]benzamide; and 2-Chloro-5-(4-chlorophenyl)-N-[(1-oxypyridin-1-ium-2-yl)methyl]benzamide.
15. A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim 1, or an optical isomer, stereoisomer or isotopic variant thereof, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
16. The pharmaceutical composition of claim 15, for use in treating or preventing a disease or condition mediated by sodium channels.
17. The pharmaceutical composition of claim 16, wherein the sodium channel is one or more selected from the group consisting of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, and NaV1.
9.
18. The pharmaceutical composition of claim 16, wherein the disease or condition is pain.
19. The pharmaceutical composition of claim 18, wherein the pain is selected from acute pain, chronic pain, neuropathic pain, inflammatory pain, visceral pain, nociceptive pain including postoperative pain; and mixed pain types involving viscera, gastrointestinal tract, cranial structures, musculoskeletal system, spine, genitourinary system, cardiovascular system and CNS (central nervous system), including cancer pain, back pain, orofacial pain and chemotherapy-induced pain.
20. The pharmaceutical composition of claim 16, wherein the disease or condition is selected from a neurological disorder, a neurodegenerative disorder, an inflammatory disorder, a gastrointestinal (GI) tract disorder, a disorder of the genito-urinary tract, a psychiatric disorder, a cardiovascular disorder, and a neuromuscular disorder. The pharmaceutical composition according to claim 15 , which is an oral preparation.
22. The pharmaceutical composition according to claim 15, further comprising an active ingredient effective for treating or preventing pain including neuropathic pain.
23. The pharmaceutical composition of claim 22, wherein the active ingredient is selected from opioid receptor agonists or antagonists, sodium channel blockers, calcium channel blockers, potassium channel blockers, pregabalin, gabapentin, antidepressants, lithium and valproate.
24. A method of treating or preventing a disease or condition mediated by sodium channels, comprising: A therapeutically effective amount of a compound as defined in claim 1, or an optical isomer, stereoisomer or isotopic variant thereof, or a pharmaceutically acceptable salt thereof is administered to a mammal in need thereof.
25. Use of a compound as defined in claim 1, or an optical isomer, stereoisomer or isotopic variant thereof, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating or preventing a disease or condition mediated by a sodium channel.
